Showing results (91-100 of 713) with videos related to
Sort By:
Pageof 72
Cardiovascular Diabetology|December 8, 2020
How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?Atsushi Tanaka, Koichi NodeCardiovascular Diabetology|May 27, 2018
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failureAtsushi Tanaka, Koichi NodeCardiovascular Diabetology|June 14, 2018
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trialsAtsushi Tanaka, Koichi NodeJournal of Cardiology|November 12, 2010
The role of vascular failure in coronary artery spasmHiroaki Kawano, Koichi NodeAmerican Journal of Physiology. Heart and Circulatory Physiology|November 15, 2011
Endothelial dysfunction as a cellular mechanism for vascular failureTetsuaki Hirase, Koichi NodeNihon Rinsho. Japanese Journal of Clinical Medicine|November 8, 2006
[Methods to evaluate the vascular endothelial function]Toshifumi Morooka, Koichi NodeNihon Rinsho. Japanese Journal of Clinical Medicine|April 8, 2009
[Vascular endothelial dysfunction]Noriko Ide, Koichi NodeNihon Rinsho. Japanese Journal of Clinical Medicine|February 18, 2010
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]Aiko Komatsu, Koichi NodeDiabetology International|August 18, 2020
Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatmentAtsushi Tanaka, Koichi NodeCardiovascular Diabetology|February 12, 2021
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitorsAtsushi Tanaka, Koichi NodePageof 72